Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$114 Mln
Revenue (TTM)
$414 Mln
Net Profit (TTM)
$40 Mln
ROE
0.4 %
ROCE
-- %
P/E Ratio
1.5
P/B Ratio
64.3
Industry P/E
--
EV/EBITDA
22.7
Div. Yield
0 %
Debt to Equity
5.6
Book Value
$--
EPS
$0.5
Face value
--
Shares outstanding
112,824,000
CFO
$253.60 Mln
EBITDA
$185.94 Mln
Net Profit
$-33.58 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Procaps Group SA (PROC)
| -53.0 | -21.4 | -24.1 | -45.0 | -48.8 | -35.7 | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|
|
Procaps Group SA (PROC)
| -22.5 | -46.2 | -6.3 | 5.6 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin... care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products. In addition, the company offers over-the-counter (OTC) consumer healthcare products through a portfolio on approximately eight therapeutic areas, including gastrointestinal, skin care, cough and cold, analgesics, urological, vitamins, minerals, and supplements in the categories of antibiotics, anti-infective, anti-parasitic, cardiovascular, feminine care, cutaneous antimycotic, pain killers, gastro intestinal, hormonals, metabolic, endocrine, nervous system, ophthalmic, osteoarticular, respiratory, diet supplements, and vitamins and minerals. Further, it provides blood glucose meters, telemonitoring products, oral anti-diabetics products, cosmeceuticals, insulin delivery systems, and other diabetes solutions; and contract drug development and manufacturing services to third party pharmaceutical companies, specializing in soft gelatin capsule technologies. The company was founded in 1977 and is based in Luxembourg, Luxembourg. Read more
Founder & Executive Chairman
Mr. Ruben Minski
Founder & Executive Chairman
Mr. Ruben Minski
Headquarters
Luxembourg
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Procaps Group SA (PROC) is $1.10 (NASDAQ) as of 11-Aug-2025 09:30 EDT. Procaps Group SA (PROC) has given a return of -48.8% in the last 3 years.
The P/E ratio of Procaps Group SA (PROC) is 1.53 times as on 11-Aug-2025.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
12.48
|
-564.11
|
|
2021
|
-9.49
|
-25.59
|
|
2020
|
-112.32
|
-4.59
|
|
2019
|
-65.32
|
-4.55
|
|
2022
|
12.48
|
-564.11
|
The 52-week high and low of Procaps Group SA (PROC) are Rs 3.78 and Rs 0.50 as of 04-Apr-2026.
Procaps Group SA (PROC) has a market capitalisation of $ 114 Mln as on 11-Aug-2025. As per SEBI classification, it is a company.
Before investing in Procaps Group SA (PROC), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.